Author

A. Welm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:mouse· 2 Assay:whole-exome sequencing· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

M. T. Lewis· 2 shared S. Li· 2 shared A. B. Saltzman· 1 shared A. Kossenkov· 1 shared A. Malovannaya· 1 shared A. Milosavljevic· 1 shared A. N. Lewis· 1 shared A. Pavlick· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. T. Lewis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

V. Petrosyan, L. E. Dobrolecki, L. Thistlethwaite, A. N. Lewis, C. Sallas, R. Rajaram, J. T. Lei, M. J. Ellis, K. Osborne, M. Rimawi, A. Pavlick, M. Shafaee, H. Dowst, A. B. Saltzman, A. Malovannaya, , M. T. Lewis

This paper identifies biomarkers of differential chemotherapy response in TNBC using a network-based approach and validates them in PDX models and clinical datasets.

bioRxiv · Aug 20, 2021 · PreprintCancer Biology

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis

Y. A. Evrard, A. SRIVASTAVA, J. Randjelovic, S. Arunachalam, C. J. Bult, H. Chen, L. Chen, M. Davies, S. Davies, B. Davis-Dusenbery, J. DiGiovanna, L. Ding, J. H. Doroshow, B. Fang, C. Frech, , J. Morris

The paper tests the reproducibility of PDX drug responses and sequence results across different labs using standardized protocols and workflows.

bioRxiv · Oct 2, 2019Cancer Biology